

Company



Contact Information

Contact Name: Peter K. Rogan, Ph.D., President
Address: 60 N. Centre Dr., London ON N5X 3X5
Email: info@cytognomix.com
Tel.: 519-661-4255
Company Website: www.cytognomix.com
Gust profile: <https://qust.com/companies/cytognomix>
Founded: London Ontario, 2009. Employees: 4

Corporate Profile

Cytognomix designs and produces proprietary cytogenetic and genomic software and reagents to personalize the diagnosis, evaluation, and management of cancer, prenatal disorders and other genetic diseases. We use bioinformatics to interpret genetic variation interpretation, to determine radiation exposures, and predict response to chemotherapies.

Product Development Focus:

We produce patented software and reagents for cytogenetic and genomic analysis, targeted to next generation sequence (NGS) and chromosome-based applications. These products are used globally by customers, including >1500 research, clinical and government laboratories, and genomics service providers. The company's marquis products are software systems. We sell a system to expedite radiation biodosimetry for emergencies and eventually therapeutic safety using cytogenetics to determine the dose to which individuals have been exposed to gamma or X radiation. We offer subscriptions for a cloud based system that interprets and validates damaging DNA sequence variants of unknown significance in complete genes and genomes. We also offer companion probe reagents aimed at enriching for complete gene sequenced, microarray designs, and fluorescence in situ hybridization, which achieve a precision and accuracy unattainable with other products. These consumable and analytical tools have been developed to personalize the diagnosis, evaluation, and management of cancer, prenatal disorders and other genetic diseases.

Business Development Objectives:

Software, Patent, or Product Licensing and Sales; Product Distribution
Customized product development: integration of CytoGnomix's application with partner products

The target market for our genome sequence interpretation products and ab initio sc technologies are research, corporate, and clinical next generation sequencing enterprises. For example, we envision providing needed services to CROs and R & D arms of biotech and pharmaceutical companies.

The target markets for our radiation biodosimetry products are reference biodosimetry and cytogenetics laboratories. Ab initio sc products (FISH, microarrays) are likely to be of interest to cytogenetics laboratories.

Products:

[MutationForecaster](#): Cloud-based software suite for interpretation of gene variants in genetic diseases and cancer

[Automated Dicentric Chromosome Identifier and Dose Estimator](#) (ADCI): Software for automating radiation cytogenetic biodosimetry

Ab initio sc technology: single copy DNA probe reagents for:

- a) [capturing and enrichment oligonucleotide pools](#) used in targeted next generation sequencing of complete genes,
- b) high resolution [fluorescence in situ hybridization](#), or
- c) targeted [genomic microarrays](#)